The psychiatrist’s role is to act as a consultant to maximize the likelihood of a successful taper and discontinuation and to minimize collateral morbidities or withdrawal complications. This slideshow features common scenarios in which a planned discontinuation of psychotropic medications occurs.
A look at the 2015 joint American Society for Adolescent Psychiatry (ASAP) and International Society for Adolescent Psychiatry and Psychology (ISAPP) Scientific Meeting in March. There, the author will be presenting two sessions that address adolescent sexuality and sexual development issues.
Some recent breakthroughs, using newly developed neuroscience investigational tools, suggest that if research resources are available, we could soon make substantial advances in understanding the mechanism of action of ECT.